Together with the English Company AgPlus Diagnostics we are developing point-of-care applications for several different biomarkers of clinical interest. One such assay is the measurement of HNL in whole blood after few minutes of activation. The aim is a rapid assay that will provide the doctor with a result  of whether the infection is caused by bacteria or virus.

In China we have formed a joint venture with Suzhou Future Medical Diagnostics, with the aim to bring HNL, ECP, EDN, MPO and other of our products out on the Chinese market. 

Discussions with other companies are underway